Business ❯ Healthcare

Biopharmaceuticals

Drug Development Company Operations Gilead Sciences Market Growth FDA Approval Industry Performance Biocon Cardiovascular Medicine Immunotherapy Company Profiles Market Competition RNA Therapeutics Oncology Corporate Partnerships Clinical Trials

Novo Nordisk Licenses Omeros’ MASP-3 Drug in Deal Worth Up to $2.1 Billion

The $340 million upfront payment strengthens Omeros’ cash position, with Novo targeting Phase 3 PNH trials after closing.

Analyst Warns Eli Lilly’s GLP-1 Lead Is Fading as CFRA Lifts Rating to Buy